Previous Article | Next Article ![]()
Infection and Immunity, May 2000, p. 2525-2534, Vol. 68, No. 5
Wyeth-Lederle Vaccines, West Henrietta, New
York
Received 5 January 2000/Returned for modification 2 February
2000/Accepted 14 February 2000
We report on the identification of a surface-exposed, highly
conserved, immunogenic nontypeable Haemophilus influenzae
(NTHi) protein, which elicits cross-reactive bactericidal antibodies against NTHi. The protein was extracted from NTHi strain P860295 with
KSCN and purified; it migrated as a single band on a sodium dodecyl
sulfate-polyacrylamide gel with an apparent molecular mass of 63 kDa.
Mouse antiserum generated against the purified protein was reactive on
whole-cell enzyme-linked immunosorbent assay (ELISA) with seven NTHi
strains and type b Eagan and Whittier strains and exhibited
bactericidal activity to homologous and heterologous NTHi strains.
However, the protein is made in small amounts in NTHi as corroborated
by immunoelectron microscopy. To further study this protein, we cloned,
sequenced, and expressed it recombinantly in Escherichia
coli. The recombinant protein is localized in the periplasm of
E. coli and has been purified to homogeneity. Both the
recombinant and native proteins possess 5'-nucleotidase
activity; hence, the protein has been called NucA. Mouse antiserum
directed against the recombinant NucA protein was reactive on Western
immunoblots and whole-cell ELISA with all H. influenzae
strains tested including Eagan and was bactericidal for two
heterologous strains tested. The antiserum also resulted in a log
reduction in bacteremia, in an infant-rat protection study with
H. influenzae type b as the challenge strain. These features suggest that NucA is a potential subunit vaccine candidate against NTHi disease.
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Identification of a Haemophilus influenzae
5'-Nucleotidase Protein: Cloning of the nucA Gene and
Immunogenicity and Characterization of the NucA Protein

*
Corresponding author. Mailing address: Wyeth-Lederle
Vaccines, 211 Bailey Rd., West Henrietta, NY 14586. Phone: (716)
273-7619. Fax: (716) 273-7515. E-mail:
zagursrj{at}war.wyeth.com.
Present address: SIGA Research Laboratories, Corvallis, OR 97333.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»